Joëlle Schutten

Effects of magnesium citrate, magnesium oxide and magnesium sulfate on arterial stiffness 121 6 All participants (n=164) Magnesium citrate (n=46) Magnesium oxide (n=46) Magnesium sulphate (n=46) Placebo (n=26) HDL cholesterol, mmol/L 1.47 ± 0.37 1.45 ± 0.33 1,52 ± 0.36 1.45 ± 0.37 1.45 ± 0.44 Triglycerides, mmol/L 1.02 (0.78-1.50) 1.02 (0.77-1.61) 1.06 (0.72-1.56) 1.02 (0.78-1.54) 0.99 (0.83-1.37) Vascular function markers c-fPWV, m/s 8.6 ± 1.6 9.0 ± 1.7 8.2 ± 1.6 8.6 ± 1.6 8.4 ± 1.5 AI@HR75, % 24.7 ± 8.6 26.9 ± 8.8 23.0 ± 8.8 24.6 ± 8.2 24.0 ± 8.2 Blood pressure SBP, mm Hg 130 ± 15 133 ± 15 127 ± 15 130 ± 15 130 ± 14 DBP, mm Hg 79 ± 9 79 ± 9 77 ± 9 79 ± 9 80 ± 8 MAP, mm Hg 96 ± 10 97 ± 10 93 ± 11 96 ± 11 97 ± 10 PP, mm Hg 51 ± 9 54 ± 9 50 ± 10 51 ± 9 50 ± 9 HR, beats/minute 60 ± 8 61 ± 9 60 ± 6 60 ± 8 61 ± 8 Plasma minerals Magnesium, mmol/L 0.85 ± 0.06 0.86 ± 0.06 0.84 ± 0.04 0.85 ± 0.09 0.87 ± 0.06 Calcium, mmol/L 2.34 ± 0.08 2.33 ± 0.08 2.34 ± 0.09 2.35 ± 0.07 2.35 ± 0.09 Potassium, mmol/L 4.1 ± 0.3 4.1 ± 0.3 4.2 ± 0.3 4.1 ± 0.3 4.1 ± 0.3 Sodium, mmol/L 140 ± 2 140 ± 2 140 ± 2 140 ± 2 141 ± 1 Phosphate, mmol/L 1.00 ± 0.14 1.00 ± 0.12 1.00 ± 0.16 0.98 ± 0.15 1.01 ± 0.13 Creatinine, µmol/L 73.0 (65.0-85.0) 73.0 (67.0-84.3) 76.0 (63.5-88.3) 71.0 (64.0-84.0) 71.0 (63.5-92.8) Albumin 44.1 ± 3.3 44.8 ± 4.9 44.3 ± 2.2 43.5 ± 2.5 43.7 ± 2.6 Urinary minerals Magnesium, mmol/24-h 5.06 ± 1.72 4.94 ± 1.47 5.13 ± 1.65 4.89 ± 2.0 5.46 ± 1.67 Calcium, mmol/24-h 4.88 ± 2.25 4.59 ± 1.95 5.29 ± 2.49 4.96 ± 2.39 4.54 ± 2.06 Potassium, mmol/24-h 87.6 ± 25.4 81.0 ± 20.3 93.4 ± 23.7 86.9 ± 26.2 90.2 ± 32.9 Values are mean ± SD, median (interquartile range) or number (percentage). BMI; body mass index, ACE-inhibitors; Angiotensin-Converting Enzyme inhibitors, ARBs; Angiotensin II Receptor Blockers, c-fPWV; carotid-to-femoral pulse wave velocity, AI@HR75; augmentation index adjusted for heart rate, SBP; systolic blood pressure, DBP; diastolic blood pressure, MAP; mean arterial pressure, PP; pulse pressure, HR; heart rate. Table 1. (Continued)

RkJQdWJsaXNoZXIy MTk4NDMw